N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation

Journal of Medicinal Chemistry

Volumn 52, Issue 9, 2009, Pages 2794-2798

  Nirschl, Alexandra A ^a   Zou, Yan ^a   Krystek Jr , Stanley R ^a   Sutton, James C ^a,b   Simpkins, Ligaya M ^a   Lupisella, John A ^a   Kuhns, Joyce E ^a   Seethala, Ramakrishna ^a   Golla, Rajasree ^a   Sleph, Paul G ^a   Beehler, Blake C ^a   Grover, Gary J ^a,c   Egan, Donald ^a   Fura, Aberra ^a   Vyas, Viral P ^a   Li, Yi Xin ^a   Sack, John S ^a   Kish, Kevin F ^a   An, Yongmi ^a   Bryson, James A ^a   Gougoutas, Jack Z ^a   DiMarco, John ^a   Zahler, Robert ^a   Ostrowski, Jacek ^a   Hamann, Lawrence G ^a,b   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Product Safety Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (7 HYDROXY 1 TRIFLUOROMETHYLTETRAHYDROPYRROLO[1,2 C]OXAZOL 3 YLIDENEAMINO] 2 CHLORO 3 METHYLBENZONITRILE; ANDROGEN RECEPTOR; IMIDAZOLIDINE DERIVATIVE; IMINE; OXAZOLIDINE DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HYDROLYSIS; IN VITRO STUDY; MALE; NONHUMAN; PH; PHARMACOPHORE; RAT;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUSCLES; OXAZOLES; PROSTATE; RATS; RECEPTORS, ANDROGEN; SUBSTRATE SPECIFICITY;

EID: 65649113574     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801583j     Document Type: Article

References (19)

1. Hijazi, R.; Cunningham, G. Andropause: Is androgen replacement therapy indicated for the aging male? Ann. Rev. Med. 2005, 56, 117-137. (Pubitemid 40305274)
2. Kaufman, J. M.; Vermeulen, A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 2005, 26, 833-876. (Pubitemid 41428540)
3. Wilson, E. M. Muscle-bound? A tissue-selective nonsteroidal androgen receptor modulator. Endocrinology 2007, 148, 1-3. (Pubitemid 46021432)
4. Rosario, E. R.; Pike, C. J. Androgen regulation of β-amyloid protein and the risk of Alzheimer's disease. Brain Res. Rev. 2008, 57, 444-453.
5. Hamann, L. G.; Mani, N. S.; Davis, R. L.; Wang, X. N.; Marschke, K. B.; Jones, T. K. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)- 8-pyridono-[5,6-g]-quinoline (LG121071). J. Med. Chem. 1999, 42, 210-212. (Pubitemid 29069855)
6. Cadilla, R.; Turnbull, P. Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr. Top. Med. Chem. 2006, 6, 245-270.
7. Gao, W.; Dalton, J. T. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discovery Today 2007, 12, 241-248. (Pubitemid 46304320)
8. Kilbourne, E. J.; Moore, W. J.; Freedman, L. P.; Nagpal, S. Selective androgen receptor modulators for frailty and osteoporosis. Curr. Opin. Invest. Drugs 2007, 8, 821-829. (Pubitemid 47511879)
9. Sun, C.; Robl, A. J.; Wang, C. T.; Huang, Y.; Kuhns, J. E.; Lupisella, J. A.; Beehler, B. C.; Golla, R.; Sleph, P. G.; Seethala, R.; Fura, A.; Krystek, S. R., Jr.; An, Y.; Malley, M.; Sack, J. S.; Salvati, M. E.; Grover, G. J.; Ostrowski, J.; Hamann, L. G. Discovery of potent, orally-active, and muscle-selective androgen receptor modulators (SARMs) based on an N-aryl-hydroxybicyclohydantoin scaffold. J. Med. Chem. 2006, 49, 7596-7599. (Pubitemid 46033650)
10. Hamann, L. G.; Manfredi, M. C.; Sun, C.; Krystek, S. R., Jr.; Huang, Y.; Bi, Y.; Augeri, D. J.; Wang, T.; Zou, Y.; Betebenner, D. A.; Fura, A.; Seethala, R.; Golla, R.; Kuhns, J. E.; Lupisella, J. A.; Darienzo, C. J.; Custer, L. L.; Price, J. L.; Johnson, J. M.; Biller, S. A.; Zahler, R.; Ostrowski, J. Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators. Bioorg. Med. Chem. Lett. 2007, 17, 1860-1864. (Pubitemid 46367685)
11. Ostrowski, J.; Driscoll, J. E.; Lupisella, J. A.; Manfredi, M. C.; Beehler, B. C.; Bi, Y.; Sun, C.; Seethala, R.; Golla, R.; Sleph, P. G.; Fura, A.; Narasimhan, N.; Krystek, S. R., Jr.; An, Y.; Kish, K. F.; Sack, J. S.; Bonacorsi, S. J.; Cao, K.; Mookhtiar, K. A.; Grover, G. J.; Hamann, L. G. Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007, 148, 4-12. (Pubitemid 46023448)
12. Miner, J. N.; Chang, W.; Chapman, M. S.; Finn, P. D.; Hong, M. H.; López, F. J.; Viveros, K. H.; Zhi, L.; Negro-Vilar, A. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology 2007, 148, 363-373. (Pubitemid 46021469)
13. Gao, W.; Reiser, P. J.; Coss, C. C.; Phelps, M. A.; Kearbey, J. D.; Miller, D. D.; Dalton, J. T. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005, 146, 4887-4897. (Pubitemid 41446627)
14. Li, J. J.; Sutton, J. C.; Nirschl, A.; Zou, Y.; Wang, H.; Sun, C.-Q.; Pi, Z.; Krystek, S. R., Jr.; Seethala, R.; Golla, R.; Sleph, P. G.; Beehler, B. C.; Grover, G. J.; Fura, A.; Vyas, V. P.; Li, C. Y.; Gougoutas, J. Z.; Galella, M. A.; Zahler, R.; Ostrowski, J.; Hamann, L. G. Discovery of potent and muscle selective androgen receptor modulators (SARMs) through scaffold modifications. J. Med. Chem. 2007, 50, 3015-3025. (Pubitemid 47001244)
15. Sack, J. S.; Kish, K. F.; Wang, C.; Attar, R. M.; Kiefer, S. E.; An, Y.; Wu, G. Y.; Scheffler, J. E.; Salvati, M. E.; Krystek, S. R., Jr.; Weinmann, R.; Einspahr, H. M. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4904-4909. (Pubitemid 32397055)
16. Kim, T. H.; Lee, G.-J. Regiocontrolled cyclization reaction of N-(2- hydroxyethyl)ureas by transfer of activation: one-pot synthesis of 2-imidazolidinones. J. Org. Chem. 1999, 64, 2941-2943. (Pubitemid 129511054)
17. Δ2-oxazines, Δ2- thiazolines, and 2-substituted benzoxazoles. Tetrahedron 1993, 49, 9353-9372.
18. Beyler, A. L.; Arnold, A.; Potts, G. O. Method for evaluating anabolic and catabolic agents in laboratory animals. J. Am. Med. Women's Assoc. 1968, 23, 708-712.
19. Chinoy, N. L.; Sheth, K. M.; Shah, V. C. A comparative histophysiological study on the normal, castrated and testosterone-treated levator ani muscle of rodents. Acta Endocrinol. 1973, 74, 389-398.